The Merck phase III MK-6482-011 study is evaluating the safety and efficacy of belzutifan and lenvatinib compared with cabozantinib as a second- or third-line therapy after progression on a PD-1/L1 agent in patients with advanced ccRCC [48,49,50]. Here, PDCD1 is linked to nonpapillary renal cell carcinoma.